EDUFLUVAC workshop on immunoassay standardisation for universal flu vaccines

The first EDUFLUVAC workshop on immunoassay standardisation for universal flu vaccines took place on 18-19 June 2015 at the National Institute for Biological Standards and Control (NIBSC), UK.  This workshop was co-organised and co-sponsored by the National Institute of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID), USA.

Worldwide experts from the universal influenza vaccine research and development field met to initiate discussion on how the community should concentrate its efforts to define the path from immunoassays validation towards harmonisation and ultimately standardisation.  The community agreed that this topic is very critical in the field and that there is a clear need for more collaboration.

 

 

Workshop participants

The EDUFLUVAC organising committee warmly thanks all participants of the workshop for their attendance and valuable contribution.

 

Scientific Organising Committee members:
David Spiro (NIH/NIAID), Ed Remarque (BPRC), Ed Schmidt (University of Groningen), Flavia D’Alessio (EVI), Odile Leroy (EVI), Othmar Engelhardt (NIBSC), Rachelle Salomon (NIH/NIAID) and Sophie Houard (EVI).

Agenda and list of participants.

Presentations:

Session 1: Established serological assays

  1. Introduction to the workshop /Othmar Engelhardt
  2. Haemagglutination inhibition & single radial haemolysis assays / Emanuele Montomoli
  3. Virus neutralisation assay / Min Levine
  4. Automated imaging and results interpretation for hemagglutination assays / Kathy Rowlen

 Session 2: Exploratory serological methods

  1. Analysis of antibody responses to the HA stem domain / Florian Krammer
  2. ELISA / Ed Remarque
  3. Approaches to evaluation of antibody-mediated enhanced infection / Hana Golding
  4. Peptide assays / micro-arrays / Marion Koopmans
  5. ELLA / Maryna Eichelberger
  6. Other NA inhibition assays / Ralf Wagner

Session 3: Cellular assays

  1. Role of T and B cells in response to influenza vaccines / Andrea Sant 
  2. ELIspot / Sarah Gilbert
  3. Intracellular Cytokine Staining (ICS) assay / Stephen Norley
  4. Cytotoxicity assays /Rory de Vries
  5. Challenges in developing M-001, a universal influenza vaccine /Tamar Ben-Yedidia

 Session 4: Assays combining antibodies and effector cells

  1. Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) assay / Rory de Vries
  2. Antibody-Dependent Respiratory Burst (ADRB) assay / Ed Remarque

 Session 5: General topics

  1. Important factors in development and assessment of novel assays for universal influenza vaccines / Harold Kleanthous
  2. Standardisation and harmonisation / Othmar Engelhardt
  3. Regulatory issues for universal influenza vaccines / Ed Schmidt
  4. Conclusions and wrap-up / Odile Leroy